Paper36911825
Hederagenin suppresses glioma cell biological activities via Nur77 in vitro study.
Dai Y and 5 others. Food Sci Nutr, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Hederagenin suppresses glioma cell biological activities via Nur77 in vitro study. Papers, record 36911825. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36911825
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36911825 | Hederagenin suppresses glioma cell biological activities via Nur77 in vitro study. | Food Sci Nutr | 2023 | https://conductscience.org/library/papers/36911825 | PubMed |
| 2 | 28485251 | Salvia miltiorrhiza extract dihydrotanshinone induces apoptosis and inhibits proliferation of glioma cells. | Bosn J Basic Med Sci | 2017 | https://conductscience.org/library/papers/28485251 | PubMed |
| 3 | 8646688 | Expression of tissue factor correlates with grade of malignancy in human glioma. | Cancer | 1996 | https://conductscience.org/library/papers/8646688 | PubMed |
| 4 | 33402591 | Optimum patient selection for irinotecan-containing regimens in metastatic colorectal cancer: Literature review and lessons from clinical practice. | Indian J Cancer | 2021 | https://conductscience.org/library/papers/33402591 | PubMed |
| 5 | 28741098 | Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy. | Cancer Chemother Pharmacol | 2017 | https://conductscience.org/library/papers/28741098 | PubMed |
| 6 | 20660371 | Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. | Cancer Res | 2010 | https://conductscience.org/library/papers/20660371 | PubMed |
| 7 | 33319659 | The Role of EGCG in Breast Cancer Prevention and Therapy. | Mini Rev Med Chem | 2021 | https://conductscience.org/library/papers/33319659 | PubMed |
| 8 | 20847229 | Regulation of Nur77 expression by β-catenin and its mitogenic effect in colon cancer cells. | FASEB J | 2011 | https://conductscience.org/library/papers/20847229 | PubMed |
| 9 | 28001084 | Resveratrol as an anti-cancer agent: A review. | Crit Rev Food Sci Nutr | 2018 | https://conductscience.org/library/papers/28001084 | PubMed |
| 10 | 27075886 | 6-Mercaptopurine attenuates tumor necrosis factor-α production in microglia through Nur77-mediated transrepression and PI3K/Akt/mTOR signaling-mediated translational regulation. | J Neuroinflammation | 2016 | https://conductscience.org/library/papers/27075886 | PubMed |
| 11 | 26393939 | Bioassay Guided Fractionation Identified Hederagenin as a Major Cytotoxic Agent from Cyclocarya paliurus Leaves. | Planta Med | 2016 | https://conductscience.org/library/papers/26393939 | PubMed |
| 12 | 11983153 | Nuclear hormone receptors in T lymphocytes. | Cell | 2002 | https://conductscience.org/library/papers/11983153 | PubMed |
| 13 | 33537093 | Hypoxia-induced Nur77 activates PI3K/Akt signaling via suppression of Dicer/let-7i-5p to induce epithelial-to-mesenchymal transition. | Theranostics | 2021 | https://conductscience.org/library/papers/33537093 | PubMed |
| 14 | 22814889 | Triterpene acids from Euscaphis japonica and assessment of their cytotoxic and anti-NO activities. | Planta Med | 2012 | https://conductscience.org/library/papers/22814889 | PubMed |
| 15 | 32284763 | Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis. | J Cancer | 2020 | https://conductscience.org/library/papers/32284763 | PubMed |
| 16 | 26267321 | The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. | Oncotarget | 2015 | https://conductscience.org/library/papers/26267321 | PubMed |
| 17 | 25342273 | Hederagenin from the leaves of ivy (Hedera helix L.) induces apoptosis in human LoVo colon cells through the mitochondrial pathway. | BMC Complement Altern Med | 2014 | https://conductscience.org/library/papers/25342273 | PubMed |
| 18 | 31718182 | Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer. | J Nat Prod | 2019 | https://conductscience.org/library/papers/31718182 | PubMed |
| 19 | 26476750 | Hederagenin as a triterpene template for the development of new antitumor compounds. | Eur J Med Chem | 2015 | https://conductscience.org/library/papers/26476750 | PubMed |
| 20 | 29335864 | Ethanol Extract of Lycopodium serratum Thunb. Attenuates Lipopolysaccharide-Induced C6 Glioma Cells Migration via Matrix Metalloproteinase-9 Expression. | Chin J Integr Med | 2018 | https://conductscience.org/library/papers/29335864 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40871546 | Recent Progress in Health Benefits of Hederagenin and Its Glycosides. | Molecules | 2025 | https://conductscience.org/library/papers/40871546 | PubMed |
| 40142049 | Current Progress of Hederagenin and Its Derivatives for Disease Therapy (2017-Present). | Molecules | 2025 | https://conductscience.org/library/papers/40142049 | PubMed |
| 39910395 | The role of natural products targeting macrophage polarization in sepsis-induced lung injury. | Chin Med | 2025 | https://conductscience.org/library/papers/39910395 | PubMed |
| 39383136 | Hederagenin regulates the migration and invasion of hepatocellular carcinoma cells through FOXO signaling pathway. | PLoS One | 2024 | https://conductscience.org/library/papers/39383136 | PubMed |
| 38962311 | An updated review of the pharmacological effects and potential mechanisms of hederagenin and its derivatives. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38962311 | PubMed |
| 37955689 | Hederagenin protects against myocardial ischemia-reperfusion injury via attenuating ALOX5-mediated ferroptosis. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/37955689 | PubMed |
| 36911825 | Hederagenin suppresses glioma cell biological activities via Nur77 in vitro study. | Food Sci Nutr | 2023 | https://conductscience.org/library/papers/36911825 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CXCR4 | 7852 | PubTator's text mining | https://conductscience.org/library/genes/7852 | NCBI Gene |
| GAPDH | 2597 | PubTator's text mining | https://conductscience.org/library/genes/2597 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
| TCF12 | 6938 | PubTator's text mining | https://conductscience.org/library/genes/6938 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36911825
GET https://conductscience.org/api/papers/v1/36911825/references?page=2